drugset / Trial / NCT00630643
NI-0401 in Active Crohn's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to assess the safety and tolerability of daily intravenous NI-0401 treatment, compared to matching placebo. And to assess the ability of NI-0401 to modulate the CD3 complex on T-cells.
Timeline
- Start
- 2006-01
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Foralumab | Monoclonal antibody | 0.05 mg | Intravenous |
| Subject | Foralumab | Monoclonal antibody | 10 mg | Intravenous |